| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.08 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.08 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.09 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.063 | 0.09 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.09 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |